基质溶素和基质溶解素在癌症发病机制及诊断中的作用
Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers.
作者信息
Piskór Barbara Maria, Przylipiak Andrzej, Dąbrowska Emilia, Niczyporuk Marek, Ławicki Sławomir
机构信息
Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.
Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, Bialystok, Poland.
出版信息
Cancer Manag Res. 2020 Oct 30;12:10949-10964. doi: 10.2147/CMAR.S235776. eCollection 2020.
Abstract
Matrix metalloproteinases (MMPs) are endopeptidases which are widely studied in terms of their role in the physiological and pathological processes in the organism. In this article, we consider usefulness of matrilysins and stromelysins in pathogenesis and diagnostic of the most common malignancies in the world, e.g., lung, breast, prostate, and colorectal cancers. In all of the mentioned cancers, matrilysins and stromelysins have a pivotal role in their development and also may have diagnostic utility. Influence to the cancerous process is connected with specific dependencies between these enzymes and components of the extracellular matrix (ECM), non-matrix components like cell surface components. All the information provided below allows to take a closer look at matrilysins and stromelysins and their functions in the cancer development.
摘要
基质金属蛋白酶（MMPs）是一种内肽酶，因其在生物体生理和病理过程中的作用而受到广泛研究。在本文中，我们探讨了基质溶素和基质溶解素在世界上最常见的恶性肿瘤（如肺癌、乳腺癌、前列腺癌和结直肠癌）的发病机制和诊断中的作用。在所有上述癌症中，基质溶素和基质溶解素在其发展过程中起关键作用，并且可能具有诊断价值。对癌过程的影响与这些酶和细胞外基质（ECM）成分、细胞表面成分等非基质成分之间的特定依赖性有关。以下提供的所有信息有助于更深入地了解基质溶素和基质溶解素及其在癌症发展中的功能。
相似文献
1
Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers.基质溶素和基质溶解素在癌症发病机制及诊断中的作用
Cancer Manag Res. 2020 Oct 30;12:10949-10964. doi: 10.2147/CMAR.S235776. eCollection 2020.
2
Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.基质金属蛋白酶在肾脏疾病中的作用：批判性评价。
Kidney Blood Press Res. 2019;44(3):298-330. doi: 10.1159/000499876. Epub 2019 Jun 11.
3
4
Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis.基质金属蛋白酶在光老化和光致癌作用中的作用。
Int J Mol Sci. 2016 Jun 2;17(6):868. doi: 10.3390/ijms17060868.
5
Biochemical and Biological Attributes of Matrix Metalloproteinases.基质金属蛋白酶的生化及生物学特性
Prog Mol Biol Transl Sci. 2017;147:1-73. doi: 10.1016/bs.pmbts.2017.02.005. Epub 2017 Mar 22.
6
Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.基质金属蛋白酶：它们在糖尿病肾病发病机制中的潜在作用。
Endocrine. 2009 Feb;35(1):1-10. doi: 10.1007/s12020-008-9114-6. Epub 2008 Oct 30.
7
Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.基质金属蛋白酶抑制剂作为无节制组织重塑和病理紊乱中的研究及治疗工具
Prog Mol Biol Transl Sci. 2017;148:355-420. doi: 10.1016/bs.pmbts.2017.04.003. Epub 2017 May 10.
8
Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.基质金属蛋白酶（MMPs）是胶原蛋白降解中的主要细胞外基质（ECM）酶，可作为抗癌药物的靶点。
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183. doi: 10.3109/14756366.2016.1161620. Epub 2016 Mar 30.
9
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.基质金属蛋白酶、血管重塑与血管疾病
Adv Pharmacol. 2018;81:241-330. doi: 10.1016/bs.apha.2017.08.002. Epub 2017 Sep 19.
10
Plasma Concentrations of Matrilysins MMP-7 and MMP-26 as Diagnostic Biomarkers in Breast Cancer.基质溶素MMP - 7和MMP - 26的血浆浓度作为乳腺癌的诊断生物标志物
J Clin Med. 2021 Apr 1;10(7):1436. doi: 10.3390/jcm10071436.
引用本文的文献
1
The impact of mitochondrial dysfunction on osteoarthritis cartilage: current insights and emerging mitochondria-targeted therapies.线粒体功能障碍对骨关节炎软骨的影响：当前见解与新兴的线粒体靶向治疗
Bone Res. 2025 Sep 1;13(1):77. doi: 10.1038/s41413-025-00460-x.
2
Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer.基质金属蛋白酶3的上调促进卵巢癌顺铂耐药
Int J Mol Sci. 2025 Apr 24;26(9):4012. doi: 10.3390/ijms26094012.
3
Association of Matrix Metalloproteinase-7 Genotypes With Nasopharyngeal Carcinoma Risk.基质金属蛋白酶-7基因多态性与鼻咽癌风险的关联
In Vivo. 2025 May-Jun;39(3):1314-1324. doi: 10.21873/invivo.13935.
4
The role of inflammatory mediators and matrix metalloproteinases (MMPs) in the progression of osteoarthritis.炎症介质和基质金属蛋白酶（MMPs）在骨关节炎进展中的作用。
Biomater Biosyst. 2024 Feb 21;13:100090. doi: 10.1016/j.bbiosy.2024.100090. eCollection 2024 Mar.
5
Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).基质金属蛋白酶抑制剂在癌症治疗中的应用：更新综述（2013-2023）。
Molecules. 2023 Jul 21;28(14):5567. doi: 10.3390/molecules28145567.
6
Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Metabolism: Insights into Health and Disease.基质金属蛋白酶及其天然抑制剂在代谢中的作用：健康与疾病的新视角。
Int J Mol Sci. 2023 Jun 26;24(13):10649. doi: 10.3390/ijms241310649.
7
Development of Matrix Metalloproteinases-Mediated Extracellular Matrix Remodeling in Regenerative Medicine: A Mini Review.基质金属蛋白酶介导的细胞外基质重塑在再生医学中的研究进展： 一个迷你综述。
Tissue Eng Regen Med. 2023 Aug;20(5):661-670. doi: 10.1007/s13770-023-00536-x. Epub 2023 May 9.
8
Plasma Levels of Metalloproteinase 3 (MMP-3) and Metalloproteinase 7 (MMP-7) as New Candidates for Tumor Biomarkers in Diagnostic of Breast Cancer Patients.血浆中基质金属蛋白酶3（MMP - 3）和基质金属蛋白酶7（MMP - 7）水平作为乳腺癌患者诊断中肿瘤生物标志物的新候选指标
J Clin Med. 2023 Mar 30;12(7):2618. doi: 10.3390/jcm12072618.
9
The roles of proteases in prostate cancer.蛋白酶在前列腺癌中的作用。
IUBMB Life. 2023 Jun;75(6):493-513. doi: 10.1002/iub.2700. Epub 2023 Jan 4.
10
Serum Level of MMP-3 and MMP-9 in Patients with Diabetes Mellitus Type 2 Infected with Epstein-Barr Virus.2 型糖尿病合并 EBV 感染患者 MMP-3 及 MMP-9 的血清水平。
Int J Mol Sci. 2022 Nov 6;23(21):13599. doi: 10.3390/ijms232113599.
本文引用的文献
1
The Role of Matrix Metalloproteinases in the Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma.基质金属蛋白酶在肝癌上皮-间质转化中的作用。
Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907. doi: 10.1155/2019/9423907. eCollection 2019.
2
The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.上皮细胞-间充质转化中的 E-钙黏蛋白和 N-钙黏蛋白转换：信号转导、治疗意义和挑战。
Cells. 2019 Sep 20;8(10):1118. doi: 10.3390/cells8101118.
3
MMP11 expression in intratumoral inflammatory cells in breast cancer.乳腺癌肿瘤内炎性细胞中的 MMP11 表达。
Histopathology. 2019 Dec;75(6):916-930. doi: 10.1111/his.13956. Epub 2019 Oct 10.
4
Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients - ROC Analysis.卵巢癌患者中所选细胞因子、基质金属蛋白酶和基质金属蛋白酶组织抑制因子的诊断效能——ROC分析
Anticancer Res. 2019 May;39(5):2575-2582. doi: 10.21873/anticanres.13380.
5
Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.基于ROC分析的细胞因子M-CSF、金属蛋白酶2（MMP-2）和组织抑制剂-2（TIMP-2）对宫颈癌患者的诊断效能
Pathol Oncol Res. 2020 Apr;26(2):791-800. doi: 10.1007/s12253-019-00626-z. Epub 2019 Feb 28.
6
Novel specific human and mouse stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) antibodies for biochemical and immunohistochemical analyses.新型人基质金属蛋白酶-1（MMP-3）和基质金属蛋白酶-2（MMP-10）特异性鼠抗体制备用于生化和免疫组织化学分析。
Wound Repair Regen. 2019 Jul;27(4):309-323. doi: 10.1111/wrr.12704. Epub 2019 Mar 7.
7
Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances.基质金属蛋白酶-9（MMP-9）作为癌症生物标志物和 MMP-9 生物传感器：最新进展。
Sensors (Basel). 2018 Sep 27;18(10):3249. doi: 10.3390/s18103249.
8
Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.血管内皮生长因子（VEGF）、基质金属蛋白酶-9（MMP-9）和基质金属蛋白酶组织抑制剂-1（TIMP-1）在乳腺癌患者中的诊断价值。采用 ROC 曲线的多变量统计分析。
Adv Med Sci. 2019 Mar;64(1):1-8. doi: 10.1016/j.advms.2018.07.002. Epub 2018 Sep 15.
9
MMP-11 as a biomarker for metastatic breast cancer by immunohistochemical-assisted imaging mass spectrometry.免疫组化辅助成像质谱法检测 MMP-11 作为转移性乳腺癌的生物标志物。
Anal Bioanal Chem. 2019 Jan;411(3):639-646. doi: 10.1007/s00216-018-1365-3. Epub 2018 Sep 15.
10
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
Zotero 插件